vs
CareDx, Inc.（CDNA）与PDF SOLUTIONS INC（PDFS）财务数据对比。点击上方公司名可切换其他公司
CareDx, Inc.的季度营收约是PDF SOLUTIONS INC的1.9倍（$117.7M vs $62.4M），CareDx, Inc.净利率更高（2.4% vs -0.1%，领先2.5%），CareDx, Inc.同比增速更快（39.0% vs 24.6%），PDF SOLUTIONS INC自由现金流更多（$7.5M vs $514.0K），过去两年PDF SOLUTIONS INC的营收复合增速更高（22.9% vs 12.9%）
CareDx是一家专注于器官移植领域的精准医疗企业，核心产品包括移植排斥反应监测诊断试剂、数字健康管理工具及配套临床服务，面向北美和欧洲市场的医疗机构及移植患者，助力提升术后患者生存质量。
PDF Solutions Inc是一家总部位于美国加利福尼亚州圣克拉拉的跨国企业，主营软件业务与工程技术服务，目前在纳斯达克交易所挂牌上市，股票代码为PDFS。
CDNA vs PDFS — 直观对比
营收规模更大
CDNA
是对方的1.9倍
$62.4M
营收增速更快
CDNA
高出14.4%
24.6%
净利率更高
CDNA
高出2.5%
-0.1%
自由现金流更多
PDFS
多$7.0M
$514.0K
两年增速更快
PDFS
近两年复合增速
12.9%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $117.7M | $62.4M |
| 净利润 | $2.8M | $-48.0K |
| 毛利率 | — | 72.9% |
| 营业利润率 | 1.0% | 5.5% |
| 净利率 | 2.4% | -0.1% |
| 营收同比 | 39.0% | 24.6% |
| 净利润同比 | — | -108.9% |
| 每股收益（稀释后） | $0.05 | $0.00 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CDNAPDFS
| Q1 26 | $117.7M | — | ||
| Q4 25 | $108.4M | $62.4M | ||
| Q3 25 | $100.1M | $57.1M | ||
| Q2 25 | $86.7M | $51.7M | ||
| Q1 25 | $84.7M | $47.8M | ||
| Q4 24 | $86.6M | $50.1M | ||
| Q3 24 | $82.9M | $46.4M | ||
| Q2 24 | $92.3M | $41.7M |
净利润CDNAPDFS
| Q1 26 | $2.8M | — | ||
| Q4 25 | $-4.1M | $-48.0K | ||
| Q3 25 | $1.7M | $1.3M | ||
| Q2 25 | $-8.6M | $1.1M | ||
| Q1 25 | $-10.4M | $-3.0M | ||
| Q4 24 | $87.7M | $539.0K | ||
| Q3 24 | $-10.6M | $2.2M | ||
| Q2 24 | $-4.6M | $1.7M |
毛利率CDNAPDFS
| Q1 26 | — | — | ||
| Q4 25 | — | 72.9% | ||
| Q3 25 | — | 72.3% | ||
| Q2 25 | — | 71.2% | ||
| Q1 25 | — | 72.9% | ||
| Q4 24 | — | 68.3% | ||
| Q3 24 | — | 73.1% | ||
| Q2 24 | — | 70.6% |
营业利润率CDNAPDFS
| Q1 26 | 1.0% | — | ||
| Q4 25 | -5.6% | 5.5% | ||
| Q3 25 | -0.2% | 8.5% | ||
| Q2 25 | -12.8% | 2.2% | ||
| Q1 25 | -15.8% | -7.4% | ||
| Q4 24 | 97.5% | 1.0% | ||
| Q3 24 | -16.6% | 4.6% | ||
| Q2 24 | -7.9% | 0.6% |
净利率CDNAPDFS
| Q1 26 | 2.4% | — | ||
| Q4 25 | -3.8% | -0.1% | ||
| Q3 25 | 1.7% | 2.3% | ||
| Q2 25 | -9.9% | 2.2% | ||
| Q1 25 | -12.2% | -6.3% | ||
| Q4 24 | 101.3% | 1.1% | ||
| Q3 24 | -12.8% | 4.8% | ||
| Q2 24 | -5.0% | 4.1% |
每股收益（稀释后）CDNAPDFS
| Q1 26 | $0.05 | — | ||
| Q4 25 | $-0.08 | $0.00 | ||
| Q3 25 | $0.03 | $0.03 | ||
| Q2 25 | $-0.16 | $0.03 | ||
| Q1 25 | $-0.19 | $-0.08 | ||
| Q4 24 | $1.60 | $0.01 | ||
| Q3 24 | $-0.20 | $0.06 | ||
| Q2 24 | $-0.09 | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $77.9M | $42.2M |
| 总债务越低越好 | — | $67.0M |
| 股东权益账面价值 | — | $271.0M |
| 总资产 | $411.1M | $418.7M |
| 负债/权益比越低杠杆越低 | — | 0.25× |
8季度趋势，按日历期对齐
现金及短期投资CDNAPDFS
| Q1 26 | $77.9M | — | ||
| Q4 25 | $177.2M | $42.2M | ||
| Q3 25 | $194.2M | $35.9M | ||
| Q2 25 | $186.3M | $40.4M | ||
| Q1 25 | $230.9M | $54.1M | ||
| Q4 24 | $260.7M | $114.9M | ||
| Q3 24 | $240.9M | $120.2M | ||
| Q2 24 | $228.9M | $117.9M |
总债务CDNAPDFS
| Q1 26 | — | — | ||
| Q4 25 | — | $67.0M | ||
| Q3 25 | — | $67.6M | ||
| Q2 25 | — | $68.1M | ||
| Q1 25 | — | $68.7M | ||
| Q4 24 | — | — | ||
| Q3 24 | $0 | — | ||
| Q2 24 | $0 | — |
股东权益CDNAPDFS
| Q1 26 | — | — | ||
| Q4 25 | $303.1M | $271.0M | ||
| Q3 25 | $311.1M | $264.4M | ||
| Q2 25 | $327.4M | $257.5M | ||
| Q1 25 | $379.3M | $249.0M | ||
| Q4 24 | $378.4M | $246.0M | ||
| Q3 24 | $273.2M | $240.5M | ||
| Q2 24 | $264.7M | $232.2M |
总资产CDNAPDFS
| Q1 26 | $411.1M | — | ||
| Q4 25 | $413.2M | $418.7M | ||
| Q3 25 | $432.3M | $406.4M | ||
| Q2 25 | $444.3M | $391.1M | ||
| Q1 25 | $489.6M | $390.0M | ||
| Q4 24 | $491.1M | $315.3M | ||
| Q3 24 | $477.0M | $307.4M | ||
| Q2 24 | $466.8M | $298.0M |
负债/权益比CDNAPDFS
| Q1 26 | — | — | ||
| Q4 25 | — | 0.25× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | — | 0.26× | ||
| Q1 25 | — | 0.28× | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.3M | $17.3M |
| 自由现金流经营现金流 - 资本支出 | $514.0K | $7.5M |
| 自由现金流率自由现金流/营收 | 0.4% | 12.1% |
| 资本支出强度资本支出/营收 | — | 15.7% |
| 现金转化率经营现金流/净利润 | 1.54× | — |
| 过去12个月自由现金流最近4个季度 | — | $-8.6M |
8季度趋势，按日历期对齐
经营现金流CDNAPDFS
| Q1 26 | $4.3M | — | ||
| Q4 25 | $21.4M | $17.3M | ||
| Q3 25 | $37.4M | $3.3M | ||
| Q2 25 | $9.9M | $-5.2M | ||
| Q1 25 | $-26.6M | $8.6M | ||
| Q4 24 | $21.9M | $1.6M | ||
| Q3 24 | $12.5M | $9.3M | ||
| Q2 24 | $18.9M | $684.0K |
自由现金流CDNAPDFS
| Q1 26 | $514.0K | — | ||
| Q4 25 | — | $7.5M | ||
| Q3 25 | — | $-2.9M | ||
| Q2 25 | — | $-13.8M | ||
| Q1 25 | — | $535.0K | ||
| Q4 24 | — | $-4.0M | ||
| Q3 24 | — | $5.1M | ||
| Q2 24 | — | $-4.6M |
自由现金流率CDNAPDFS
| Q1 26 | 0.4% | — | ||
| Q4 25 | — | 12.1% | ||
| Q3 25 | — | -5.1% | ||
| Q2 25 | — | -26.6% | ||
| Q1 25 | — | 1.1% | ||
| Q4 24 | — | -8.0% | ||
| Q3 24 | — | 11.0% | ||
| Q2 24 | — | -11.1% |
资本支出强度CDNAPDFS
| Q1 26 | — | — | ||
| Q4 25 | — | 15.7% | ||
| Q3 25 | — | 10.8% | ||
| Q2 25 | — | 16.5% | ||
| Q1 25 | — | 17.0% | ||
| Q4 24 | — | 11.3% | ||
| Q3 24 | — | 9.0% | ||
| Q2 24 | — | 12.8% |
现金转化率CDNAPDFS
| Q1 26 | 1.54× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 22.30× | 2.54× | ||
| Q2 25 | — | -4.55× | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.25× | 2.98× | ||
| Q3 24 | — | 4.20× | ||
| Q2 24 | — | 0.40× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CDNA
| Financial Results Total | $85.0M | 72% |
| Patient and digital solutions revenue | $16.0M | 14% |
| Product revenue | $10.3M | 9% |
| Other | $6.4M | 5% |
PDFS
| Volumebased | $38.0M | 61% |
| Other | $24.4M | 39% |
